Philip Hodges Net Worth

The estimated Net Worth of Philip Hodges is at least $206 Thousand dollars as of 1 March 2021. Mr. Hodges owns over 6,000 units of Altimmune Inc stock worth over $62,601 and over the last 6 years he sold ALT stock worth over $143,105. In addition, he makes $0 as Independent Director at Altimmune Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Hodges ALT stock SEC Form 4 insiders trading

Philip has made over 3 trades of the Altimmune Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 6,000 units of ALT stock worth $96,480 on 1 March 2021.

The largest trade he's ever made was exercising 16,850 units of Altimmune Inc stock on 24 September 2020 worth over $120,815. On average, Philip trades about 2,953 units every 18 days since 2019. As of 1 March 2021 he still owns at least 8,731 units of Altimmune Inc stock.

You can see the complete history of Mr. Hodges stock trades at the bottom of the page.

Philip Hodges biography

Philip L. Hodges serves as Independent Director of the Company. Mr. Hodges is Managing Partner of Redmont Capital, a private equity firm located in Birmingham, Alabama, which he joined at its inception in 1997. Redmont Capital is a co-founder of Altimmune. Mr. Hodges’ investment strategy is focused on high-growth small businesses within the health care, life science and technology sectors. He currently serves as a director for several of the firm’s portfolio companies. Mr. Hodges holds a Bachelor of Science in Business Administration from the Brock School of Business at Samford University. Mr. Hodges brings significant experience as a life science investor and co-founder to Altimmune’s board of directors.

How old is Philip Hodges?

Philip Hodges is 51, he's been the Independent Director of Altimmune Inc since 2017. There are 13 older and 1 younger executives at Altimmune Inc. The oldest executive at Altimmune Inc is David Drutz, 81, who is the Independent Director.

What's Philip Hodges's mailing address?

Philip's mailing address filed with the SEC is C/O ALTIMMUNE, INC.,, 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG, MD, 20878.

Insiders trading at Altimmune Inc

Over the last 7 years, insiders at Altimmune Inc have traded over $2,557,810 worth of Altimmune Inc stock and bought 3,362,060 units worth $23,898,779 . The most active insiders traders include Bioventures Ltd Novartis Ag..., Healthcare Capital Partners..., and Mitchel Sayare. On average, Altimmune Inc executives and independent directors trade stock every 35 days with the average trade being worth of $432,889. The most recent stock trade was executed by David Drutz on 19 August 2024, trading 41,750 units of ALT stock currently worth $106,463.

What does Altimmune Inc do?

altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current

Complete history of Mr. Hodges stock trades at Altimmune Inc

Altimmune Inc executives and stock owners

Altimmune Inc executives and other stock owners filed with the SEC include:

• Dr. Vipin K. Garg Ph.D.,
  Pres, CEO & Director
• William Brown,
  Chief Financial Officer, Principal Accounting Officer
• Dr. Matthew Scott Harris M.D., MS, FCAP, AGAF,
  Chief Medical Officer
• Vipin Garg,
  President, Chief Executive Officer, Director
• Dr. M. Scot Roberts,
  Chief Scientific Officer
• John Gill,
  Independent Director
• M. Scott Harris,
  Chief Medical Officer
• Mitchel Sayare,
  Chairman of the Board
• Ashley Robinson,
  IR Contact Officer
• Klaus Schafer,
  Independent Director
• Wayne Pisano,
  Independent Director
• Philip Hodges,
  Independent Director
• David Drutz,
  Independent Director
• Diane Jorkasky,
  Director
• M. Scot Roberts,
  Chief Scientific Officer
• José Ochoa,
  Chief Bus. Officer
• Bertrand Georges Ph.D.,
  Chief Technology Officer
• Richard I. Eisenstadt M.B.A.,
  CFO and Principal Financial & Accounting Officer
• Sybil Tasker,
  Chief Medical Officer
• Philip Hodges,
  Director
• Derace L Schaffer,
  Director
• Capital S.A.S. Truffle,
  10% owner
• Bioventures Ltd Novartis Ag...,
  
• William Enright,
  President and CEO
• Elizabeth Czerepak,
  CFO and EVP Corp. Development
• Healthcare Capital Partners...,
  
• Pharmaceutical Holdings Llc...,
  10% owner
• Richard I Eisenstadt,
  Chief Financial Officer
• Raymond M Jordt,
  Chief Business Officer
• Catherine A. Sohn,
  Director
• Andrew Shutterly,
  Acting Chief Financial Officer